SLC6A4 and Parkinson disease: The following SERT-selective MAUIs have been used in studies in PD and/or related animal models: citalopram, clomipramine, duloxetine, escitalopram, fenfluramine, fluoxetine, fluvoxamine, imipramine, paroxetine, R-MDMA, sertraline, trazodone, trimipramine, UWA-122, and venlafaxine.